安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- J J files intravesical bladder cancer drug TAR-200 in US
Johnson Johnson has kicked off a marketing application in the US for TAR-200 as a treatment for a form of bladder cancer, using a novel technology that releases the drug intravesically, or
- J J’s ‘Pretzel’ Drug-Device Combo Scores in Mid-Stage Bladder Cancer . . .
Johnson Johnson on Friday unveiled updated data from its Phase IIb SunRISe-1 study, which found that its investigational drug-device combination TAR-200 can induce rapid complete response in patients with high-risk non-muscle invasive bladder cancer
- J J speeds into new bladder cancer trial - ApexOnco
J J already markets erdafitinib in metastatic bladder cancer, where it is branded Balversa With its new formulation the group hopes to go earlier in the disease and address a greater proportion of patients The Taris system is placed within the bladder, where it releases its payload
- TAR-200 - General Overview
TAR-200 (JNJ-17000139) is an investigational intravesical system that is designed to provide local release of gemcitabine in the bladder TAR-200 contains gemcitabine and urea mini tablets within a dual-lumen silicone tube for gradual release of gemcitabine by an osmotic delivery mechanism throughout the prescribed indwelling period 1-7
- J J puts ImmunityBio on defense mode in bladder cancer
J J’s ambition will likely bring TAR-200—an intravesical system designed to locally deliver the chemotherapy gemcitabine into the bladder—into competition with ImmunityBio’s immunotherapy
- New data from J J’s bladder cancer drug-device trial strengthens . . .
Johnson Johnson (J J) has reported more data supporting the efficacy of its intravesical drug release system TAR-200 in patients with Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC)
- TARIS | [site:name]
The TARIS system is a first-in-class clinical stage platform to evaluate novel, locally delivered therapeutics to patients with bladder cancer, and potentially other types of cancer It is a silicone-based delivery device that allows for the continuous release of medication directly to tumors in the bladder
- J J Looks To Overcome Drug-Delivery Limitations In Bladder Cancer With . . .
Johnson Johnson is positioning its drug and device combination, TAR-200, to overcome limitations that have often dogged the ability of various drugs to treat non-muscle-invasive bladder cancer (NMIBC), and it got a boost from Phase IIb data presented at a medical conference over the weekend
|
|
|